The tweet was deleted by the author.
But we saved everything 🙂.
The proportion of GLP-1 prescriptions requiring prior authorization has soared from just 3-5 percent in 2020 to nearly 100 percent today, according to Definitive Healthcare.
This dramatic change is creating significant challenges for providers, patients, and pharmaceutical companies, intensifying the administrative workload and threatening timely access to essential therapies. Industry analysts note that prior authorization processes, often implemented as a cost-control measure by payers, are slowing the delivery of newer medications that have seen rapid growth. Definitive Healthcare stresses that stakeholders must adapt quickly to this new landscape to support patient outcomes and manage operational strain.